Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Move “Beyond Our Borders” Begins With China

This article was originally published in PharmAsia News

Executive Summary

Congressional concerns over inspection oversight in the midst of a heparin safety scare have not dampened FDA's efforts to highlight its new overseas initiative, "FDA Beyond Our Borders.
Advertisement

Related Content

U.S. FDA, PDA Kick Off First Conference On Quality Systems For China’s Manufacturers, Suppliers
U.S. FDA Triples Estimate On Deaths Following Allergic Reaction To Blood Thinner Heparin
GMP Inspection Results Can No Longer Stay Within Borders, Says U.S. FDA
U.S. FDA Plans Permanent Offices In China In Wake Of Heparin Scare
U.S. FDA Inspected “Wrong” Heparin API Manufacturer – Compliance Official
U.S. FDA’s Response To Heparin Scare Made With “Alacrity And Sound Judgment” – von Eschenbach
U.S. FDA’s Response To Heparin Scare Made With “Alacrity And Sound Judgment” – von Eschenbach
Import Safety Agreement Further Entwines FDA/China Regulatory Process
FDA Says Lack of Resources and Staff Hinder Its Foreign Inspections
FDA Needs New Regulatory Model In Face Of Globalization, Woodcock Says
Advertisement
UsernamePublicRestriction

Register

SC068127

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel